Erythropoietin plus insulin‐like growth factor‐I protects against neuronal damage in a murine model of human immunodeficiency virus‐associated neurocognitive disorders

Prolonged human immunodeficiency virus‐1 (HIV‐1) infection leads to neurological debilitation, including motor dysfunction and frank dementia. Although pharmacological control of HIV infection is now possible, HIV‐associated neurocognitive disorders (HAND) remain intractable. Here, we report that chronic treatment with erythropoietin (EPO) and insulin‐like growth factor‐I (IGF‐I) protects against HIV/gp120‐mediated neuronal damage in culture and in vivo.

[1]  S. Lipton,et al.  Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. , 2009, Journal of neurosurgery.

[2]  E. Masliah,et al.  Chemokine receptors and neurotrophic factors: Potential therapy against aids dementia? , 2008, Journal of neuroscience research.

[3]  Lynette M. Smith,et al.  Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis1 , 2007, The Journal of Immunology.

[4]  S. Lipton,et al.  Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study , 2007, AIDS.

[5]  W. Pardridge.  Brain Drug Development and Brain Drug Targeting , 2007, Pharmaceutical Research.

[6]  E. Masliah,et al.  Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation , 2007, The Journal of Neuroscience.

[7]  Tudor A. Fulga,et al.  Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo , 2007, Nature Cell Biology.

[8]  K. Beyreuther,et al.  Teasing out the tangles , 2006, Nature Network Boston.

[9]  S. Lipton,et al.  Suppression of Cyclin-Dependent Kinase 5 Activation by Amyloid Precursor Protein: A Novel Excitoprotective Mechanism Involving Modulation of Tau Phosphorylation , 2005, The Journal of Neuroscience.

[10]  Wei-Ping Zhang,et al.  Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia , 2005, Neuroscience Letters.

[11]  H. Gendelman,et al.  Inhibition of Indoleamine 2 , 3-dioxygenase ( IDO ) enhances elimination of virus-infected macrophages in animal model of HIV-1 encephalitis , 2005 .

[12]  H. Xiong,et al.  Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis , 2005, The Journal of Neuroscience.

[13]  A. Cerami,et al.  Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.

[14]  E. Masliah,et al.  Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients , 2005, AIDS.

[15]  R. G. Thorne,et al.  Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.

[16]  J. McArthur.  HIV dementia: an evolving disease , 2004, Journal of Neuroimmunology.

[17]  M. Herrmann,et al.  Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease , 2004, Metabolic Brain Disease.

[18]  G. Johnson,et al.  Tau phosphorylation in neuronal cell function and dysfunction , 2004, Journal of Cell Science.

[19]  M. Kaul,et al.  Erythropoietin protects cerebrocortical neurons from HIV-1/gp120-induced damage , 2004, Neuroreport.

[20]  Wenhua Zheng,et al.  Insulin‐like growth factor 1 prevents neuronal cell death induced by corticosterone through activation of the PI3k/Akt pathway , 2004, Journal of neuroscience research.

[21]  M. Rosenzweig,et al.  The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. , 2004, Journal of pain and symptom management.

[22]  S. Lipton,et al.  Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Li-Huei Tsai,et al.  Aberrant Cdk5 Activation by p25 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles , 2003, Neuron.

[24]  D. Kolson.  Neuropathogenesis of central nervous system HIV-1 infection. , 2002, Clinics in laboratory medicine.

[25]  Jan Born,et al.  Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.

[26]  Junying Yuan,et al.  Caspase Cascades in Human Immunodeficiency Virus-Associated Neurodegeneration , 2002, The Journal of Neuroscience.

[27]  Stuart A. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[28]  W. Frey,et al.  Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage , 2001, Journal of the Neurological Sciences.

[29]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[30]  Stuart A. Lipton,et al.  Pathways to neuronal injury and apoptosis in HIV-associated dementia , 2001, Nature.

[31]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Kalloniatis,et al.  Endogenous IGF‐1 regulates the neuronal differentiation of adult stem cells , 2000, Journal of neuroscience research.

[33]  M. Bähr,et al.  Insulin-Like Growth Factor-I Protects Axotomized Rat Retinal Ganglion Cells from Secondary Death via PI3-K-Dependent Akt Phosphorylation and Inhibition of Caspase-3 In Vivo , 2000, The Journal of Neuroscience.

[34]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[35]  H. Braak,et al.  Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .

[36]  M. Kaul,et al.  Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Braak,et al.  Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. , 1999, Journal of neuropathology and experimental neurology.

[38]  S. Doré,et al.  Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. , 1997, Trends in neurosciences.

[39]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[40]  M. Billingsley,et al.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.

[41]  E. Morishita,et al.  Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death , 1996, Neuroscience.

[42]  L. Mucke,et al.  Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis. , 1996, The Journal of clinical investigation.

[43]  C. Petito,et al.  Evidence of apoptotic cell death in HIV encephalitis. , 1995, The American journal of pathology.

[44]  R. Reinhardt,et al.  Insulin-like growth factors cross the blood-brain barrier. , 1994, Endocrinology.

[45]  R. Marcus,et al.  Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. , 1994, The Journal of clinical endocrinology and metabolism.

[46]  S. Miller,et al.  Effects of IGF-I on renal function in end-stage chronic renal failure. , 1994, Kidney international.

[47]  R. Mrak,et al.  Glial Cytokines as Neuropathogenic Factors in HIV Infection: Pathogenic Similarities to Alzheimer's Disease , 1994, Journal of neuropathology and experimental neurology.

[48]  S. Schwartz,et al.  Adverse Effects of Recombinant Human Insulin-like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients , 1994, Diabetes.

[49]  L. Mucke,et al.  Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. , 1994, Nature.

[50]  G. Singbartl.  Adverse events of erythropoietin in long-term and in acute/short-term treatment. , 1994, The Clinical investigator.

[51]  A. Raine.  HYPERTENSION, BLOOD VISCOSITY, AND CARDIOVASCULAR MORBIDITY IN RENAL FAILURE: IMPLICATIONS OF ERYTHROPOIETIN THERAPY , 1988, The Lancet.

[52]  M. Adinolfi.  INHIBITION OF MITOSIS OF MATERNAL LYMPHOCYTES BY FETAL CELLS , 1976, The Lancet.